News
-
-
PRESS RELEASE
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Transgene to present VacDesignR® tool at ESMO-AI 2025 for optimized cancer vaccine design. Tool enhances virus efficiency and yield for individualized therapies -
-
-
-
PRESS RELEASE
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent's BT-001 oncolytic virus in combination with pembrolizumab shows positive antitumoral activity in refractory tumors. Exciting clinical data presented at ESMO 2025 -
-
PRESS RELEASE
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Transgene to participate in upcoming meetings with biotech industry leaders to discuss positive clinical data on neoantigen cancer vaccine TG4050 and present innovative immunotherapies. Learn more at www.transgene.com -
-
PRESS RELEASE
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
Transgene and NEC reveal positive data on TG4050 cancer vaccine, demonstrating durable disease-free survival and sustained T cell responses at 24 months in HPV-negative head and neck cancer. Conference call on June 6, 2025
